Fund moves

Ionis Pharmaceuticals (IONS): Eventide Asset Management, LLC opened a new position $45.5M

Eventide Asset Management, LLC opened a new position in Ionis Pharmaceuticals, per its Q4 2025 13F.

575K
Shares reported
0.71%
Disclosed portfolio weight
$45.5M
Reported value
Holdings as of
Dec 31, 2025
Filed
Feb 13, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Jan 12, 2026Company filing · Form 8-K · ResultsReported its results

What came next

  1. Feb 25, 2026Company filing · Form 8-K · ResultsReported its results
  2. Mar 3, 2026Company filing · Form 8-K · Executive change, Reg FDChanged a top executive or board member, and shared information with investors“On March 3, 2026, B. Lynne Parshall, a member of the Board of Directors (“ Board ”) of Ionis Pharmaceuticals, Inc. (the “ Company ”), and member of the Compliance Committee and Finance Committee of the Board, notified the Company that she will be retiring from the Board at the end of her current term and not seeking re-election at the Company’s 2026 Annual Meeting of Stockholders (the “ 2026 Annual Meeting ”).”
  3. Apr 29, 2026Company filing · Form 8-K · ResultsReported its results
  4. Jun 4, 2026Company filing · Form 8-K · Executive change, Shareholder voteChanged a top executive or board member, and held a shareholder vote (and 1 more item)“On June 4, 2026, the Board of Directors (“ Board ”) of Ionis Pharmaceuticals, Inc. (the “ Company ”) appointed Ludwig N. Hantson as a member of the Company’s Board effective June 4, 2026, immediately following the Company’s 2026 Annual Meeting of Stockholders.”
View the official recordSEC Form 13F-HR

How to read SEC Form 13F-HR

Form 13F is the quarterly report in which investment managers that oversee $100 million or more list the US-listed stocks and some other securities they held on the last day of the quarter.

Full guide: What is an SEC Form 13F?

What else is on file for Ionis Pharmaceuticals

For Ionis Pharmaceuticals, OQRO holds 4 insider filings (SEC Form 4 or Form 144) and 1 fund holdings report (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its IONS page.

How this filing works

Explore the data

Other disclosures at Ionis Pharmaceuticals

Everything OQRO holds on this company is on its IONS page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

OQRO is free for everyone. No card, no trial

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data